-transparent.png){kind=logo}
The effect of the possible influence of a new calcium antagonist, PY 108-068, on regional CBF was studied in patients suffering acute ischemic stroke. The dosage was 1.5 + 2.5 mg intravenously in six patients (series 1) and 2.5 + 5.0 mg intravenously in five other patients (series 2). CBF was measured before and after treatment by xenon-133 inhalation and single-photon emission computed tomography (Tomomatic 64). In the first series, no changes in hemispheric CBF, MABP, or clinical symptoms were noted after treatment, but one patient showed an increase of CBF in part of the periinfarct area. In the second series, slight increases in mean hemispheric flow values were seen, but in three of the five patients CBF decreased even further in the ischemic area. MABP decreased by 13%, and the clinical symptoms were unchanged.
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
January 1985,
General pharmacology,
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
August 1986,
Chest,
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
January 1986,
The American review of respiratory disease,
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
January 1984,
Stroke,
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
February 1983,
British journal of pharmacology,
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
January 1983,
Journal of cardiovascular pharmacology,
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
January 1982,
Journal of cardiovascular pharmacology,
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
January 1986,
The American journal of cardiology,
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
January 1986,
European journal of clinical pharmacology,
S Vorstrup, and
A Andersen, and
N Blegvad, and
O B Paulson
January 1995,
Brain research bulletin,
